The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial

BACKGROUND: Thrombolysis is of net benefit in patients with acute ischaemic stroke, who are younger than 80 years of age and are treated within 4·5 h of onset. The third International Stroke Trial (IST-3) sought to determine whether a wider range of patients might benefit up to 6 h from stroke onset...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Publishing Group 2012
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3386495/
https://www.ncbi.nlm.nih.gov/pubmed/22632908
http://dx.doi.org/10.1016/S0140-6736(12)60768-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3386495/
https://www.ncbi.nlm.nih.gov/pubmed/22632908
http://dx.doi.org/10.1016/S0140-6736(12)60768-5

Ejemplares similares